Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib, sintilimab, and chemotherapy combinations as first-line treatment for extensive-stage small cell lung cancer
ChiCTR2200062048Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jul 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of surufatinib, sintilimab, etoposide, carboplatin and cisplatin in small cell lung cancer (SCLC) (4 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Objective response rate. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
surufatinibsintilimabetoposidecarboplatincisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2200062048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062048.